Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) has been assigned a $28.00 price objective by Jefferies Group in a research note issued to investors on Thursday. The firm presently has a a “buy” rating on the specialty pharmaceutical company’s stock. Jefferies Group’s price objective would indicate a potential upside of 29.99% from the company’s current price.

Several other research analysts have also commented on SUPN. Zacks Investment Research raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 price objective on the stock in a research report on Wednesday, July 6th. Northland Securities lowered Supernus Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 target price on the stock. in a research report on Monday, July 18th. Finally, Piper Jaffray Cos. lowered Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $23.00 target price on the stock. in a research report on Monday, July 18th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Supernus Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $25.25.

Supernus Pharmaceuticals (NASDAQ:SUPN) traded up 2.484% during mid-day trading on Thursday, reaching $22.075. The company’s stock had a trading volume of 769,114 shares. The stock’s 50-day moving average is $23.58 and its 200-day moving average is $20.23. The firm has a market capitalization of $1.09 billion, a PE ratio of 45.051 and a beta of 1.73. Supernus Pharmaceuticals has a 12 month low of $9.51 and a 12 month high of $26.84.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Tuesday, August 2nd. The specialty pharmaceutical company reported $0.18 EPS for the quarter, beating the consensus estimate of $0.13 by $0.05. Supernus Pharmaceuticals had a return on equity of 20.99% and a net margin of 14.94%. The company had revenue of $50.40 million for the quarter, compared to analyst estimates of $49.67 million. During the same period last year, the company posted $0.03 earnings per share. The firm’s revenue was up 43.6% compared to the same quarter last year. On average, equities analysts anticipate that Supernus Pharmaceuticals will post $0.68 EPS for the current year.

In other news, CFO Gregory S. Patrick sold 2,000 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, September 16th. The stock was sold at an average price of $25.00, for a total transaction of $50,000.00. Following the sale, the chief financial officer now directly owns 3,616 shares of the company’s stock, valued at $90,400. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 6.10% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Royal Bank of Canada increased its position in Supernus Pharmaceuticals by 70.9% in the first quarter. Royal Bank of Canada now owns 21,946 shares of the specialty pharmaceutical company’s stock worth $335,000 after buying an additional 9,104 shares during the period. Panagora Asset Management Inc. increased its position in Supernus Pharmaceuticals by 31.5% in the first quarter. Panagora Asset Management Inc. now owns 302,872 shares of the specialty pharmaceutical company’s stock worth $4,619,000 after buying an additional 72,517 shares during the period. AlphaOne Investment Services LLC increased its position in Supernus Pharmaceuticals by 3.3% in the first quarter. AlphaOne Investment Services LLC now owns 247,917 shares of the specialty pharmaceutical company’s stock worth $3,781,000 after buying an additional 7,874 shares during the period. LPL Financial LLC increased its position in Supernus Pharmaceuticals by 52.0% in the first quarter. LPL Financial LLC now owns 58,511 shares of the specialty pharmaceutical company’s stock worth $946,000 after buying an additional 20,025 shares during the period. Finally, Bellevue Group AG purchased a new position in Supernus Pharmaceuticals during the first quarter worth approximately $6,725,000. Institutional investors and hedge funds own 94.66% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).

5 Day Chart for NASDAQ:SUPN

Receive News & Stock Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.